Synthetic antigen-augmented SynNotch CAR T Cell therapy for Glioblastoma: a conceptual design review

Glioblastoma is the most aggressive primary brain tumor and remains highly resistant to surgery, radiotherapy, chemotherapy, and current immunotherapies because of antigen heterogeneity, immune suppression, and a dense extracellular matrix. Although EGFRvIII-targeted CAR T-cell therapies have demonstrated biological activity, clinical benefit has been limited by antigen escape, poor persistence, and restricted tumor infiltration. This conceptual design review proposes a multimodal post-resection strategy that integrates complementary immunoengineering technologies to address these barriers. An EGFRvIII-specific synthetic Notch (SynNotch) receptor is proposed to induce expression of an IL13Rα2-targeted CAR only after tumor recognition, improving specificity while reducing antigen escape. A CRISPR-mediated PD-1 knockout is incorporated to enhance T-cell persistence, while reactive oxygen species (ROS)-responsive hyaluronidase nanogels are designed to improve migration through the hyaluronic acid-rich extracellular matrix. A visible-light photocrosslinkable hyaluronic acid methacrylate hydrogel containing hypoxia-responsive IL-15 is further proposed to provide sustained, localized cytokine support within the resection cavity. Beyond this integrated therapeutic framework, the review discusses synthetic antigen engineering as a future strategy to further overcome antigen escape by introducing programmable tumor targets that may broaden CAR T-cell applicability in heterogeneous glioblastoma. Together, these approaches integrate advances in synthetic biology, biomaterials, and immunoengineering into a unified conceptual platform for improving CAR T-cell therapy against glioblastoma. Although experimental validation remains necessary, this framework identifies a rational direction for future translational investigation.